An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.

The findings highlight the overall safety of lanreotide autogel in the management of NETs, with a focus on its efficacy in controlling hormone secretion, tumor progression, and symptom management. New safety concerns and precautions are also addressed to assist healthcare providers in making informed decisions when prescribing lanreotide autogel.